|
||||||||||||||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Myron Zitt, MD
State University of New York at Stony Brook
Ketan K. Sheth, MD, MBA
Private Practice
Lafayette Allergy and Asthma Clinic
Adjunct Associate Professor Clinical Pharmacy
Purdue University
Clinical Assistant Professor of Pediatrics
Indiana University School of Medicine
Lafayette, Indiana
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Muredach P. Reilly, MB
Assistant Professor of Medicine and Pharmacology
University of Pennsylvania School of Medicine
Philadelphia, PA
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
Philadelphia, PA
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
Louis Kuritzky, MD
Clinical Assistant Professor
Dept. of Community Health & Family Medicine
University of Florida
Gainesville, FL
Anthony J. Lembo, MD
Assistant Professor of Medicine
Department of Medicine, Division of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA
Overview
This program will underscore the need for early, aggressive, combination BP treatment in order to reach JNC 7 goals, in light of the effect hypertension and diabetes has on the pathogenesis of hypertensive renal damage. It will explain the mechanisms of action of the various antihypertensive drug classes and how clinicians can use this understanding when selecting a drug regimen. Based on recent and ongoing trials, the safest and most efficacious drug combinations will be discussed.
Objectives
Develop appropriate combination therapy regimens individualized to each diabetic hypertensive patientŐs established risk and comorbid conditions
Demonstrate an understanding of the role of Renin-Aniotensin-Aldosterone System blockers in the treatment of hypertension, the prevention of new onset diabetes, and prevention of progression in diabetic nephropathy by selecting the most appropriate treatment regimen for diabetic hypertensive patients
Faculty
Philip Altus, MD, MACP
Professor of Medicine Emeritus
University of South Florida
Tampa, FL
Domenic A. Sica, MD
Professor of Medicine
Medical College of Virginia
Virginia Commonwealth University
Richmond, VA
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Gregory Brotzman, MD
Martin C. Mahoney, MD, PhD
Director, Cancer Prevention & Detection Center
Roswell Park Cancer Institute
Associate Professor of Family Medicine
State University of New York at Buffalo
Buffalo, NY
Overview
More than 20 million people are affected by diabetes and of this population nearly 65% will suffer early cardiovascular death. To effectively treat diabetes and reduce the risk of a cardiovascular event, glucose levels must be monitored and quickly controlled through changes in intervention, as outlined by the ADA/EASD treatment algorithm. Recent data provided by the National Health and Nutrition Examination Surveys (NHANES) revealed that there is some overall improvement in reaching the appropriate treatment standards, however, with the number of diabetes cases increasing by 1.5 million each year and the recent labeling changes affecting therapeutic options, it is more important than ever to be familiar with the pharmacologic treatment options for type 2 diabetes and the associated cardiovascular risk.
Objectives
Identify the current goals for A1C, blood pressure, and lipid levels set forth by the American Diabetes Association and apply them to the treatment strategies listed on the ADA/EASD algorithm in an effort to choose the best therapeutic option for each individual patient
Assess when patients with type 2 diabetes require cardiovascular risk reduction in addition to glycemic control and develop evidence-based approaches to treatment based on the ADA/EASD algorithm by reviewing adverse events
Faculty
Burton Sobel, MD
Professor of Medicine and Director
Cardiovascular Research Institute
University of Vermont College of Medicine
Colchester Research Facility and Consulting Cardiologist
Fletcher Allen Health Care
Burlington, VT
Stephen Clement, MD
Associate Professor of Medicine
Division of Endocrinology
Georgetown University Medical Center
Acting Chief, Division of Endocrinology
Georgetown University Hospital
Washington, DC
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the epidemiology and public health burden of herpes zoster and its most common complication, postherpetic neuralgia (PHN)
Discuss the benefits and limitations of current pharmacotherapies for herpes zoster and Postherpetic neuralgia (PHN), and evaluate clinical trial data on the efficacy and safety of herpes zoster vaccination
Faculty
Rosemary C. Polomano, PhD, RN, FAAN
Associate Professor of Pain Practice
University of Pennsylvania School of Nursing
Clinician Educator
Hospital of the University of Pennsylvania
Philadelphia, PA
Malcolm Fraser, MD, CMD
President, Bay Geriatrics
St. Petersburg, FL
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
Vincent Martin, MD
Professor of Clinical Medicine, University of Cincinnati
Cincinnati, OH
Brian Koffman, MDCM
Clinical Professor, Department of Family Medicine
Keck School of Medicine, USC Family Practice
St. Jude Heritage Medical Group
Diamond Bar, CA
Overview
This course considers the growing complaint of insomnia in the primary care practice and offers practical approaches to diagnosis and treatment. With the immense importance of sleep, and the need to proactively address insomnia patients in the practice, this course will provide key steps to insomnia management leading to improved patient outcomes and overall health.
Objectives
Describe a patient-centered approach to the diagnosis of insomnia and development of a treatment plan
Apply the elements of a risk/benefit analysis for choosing a pharmacologic option to various patients at risk
Faculty
Karl Doghramji, MD
Medical Director, Sleep Disorders Center
Thomas Jefferson University
Philadelphia, PA
Paul Doghramji, MD
Overview
PAD is frequently unrecognized and many patients at risk are currently not identified and treated. Current estimates are that 8-12 million Americans have PAD, with the highest incidence among those over 70 years of age, regardless of health status, and people over 50 years of age with diabetes mellitus.
This lecture will overview the tremendous risk associated with PAD, discuss the major risk factors for developing PAD, and highlight the role of primary care in detecting and diagnosing the condition through increased use of ABI screening. Current therapies will be discussed including symptom improvement and prevention of future CV events with an emphasis on patient compliance issues.
Objectives
Name the two types of patients most at risk of PAD who should be screened utilizing ABI
Recognize the need and benefits of ABI, and describe what readings are considered abnormal
Faculty
Judith G. Regensteiner, PhD
Professor of Medicine
University of Colorado Health Science Center
Denver, CO
Lawrence E. Mieczkowski, MD
Clinical Associate Professor of Medicine
Wright State University School of Medicine
Medical Director, Center for Cardiometabolic Treatment
Dayton, OH
Overview
TBD
Objectives
Faculty